NCT00717756已完成2 期
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 3
- 主要终点
- Response Rate by Recist Criteria
研究概览
简要总结
This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.
详细描述
This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed HCC or triple phase CT consistent with HCC in a patient with known cirrhosis and AFP > 200 ng/ml.
- •Disease not amenable to curative surgical resection
- •Patients must have been previously treated with sorafenib. Patients who are unable to receive sorafenib due to financial reasons are also eligible.
- •All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
- •No previous thalidomide.
- •Patients must have radiologically assessable tumor.
- •ECOG performance status of 0-2 at study entry.
- •Understand and voluntarily sign an informed consent form.
- •Age >18 years at the time of signing the informed consent form.
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Laboratory test results within these ranges:
- •Absolute neutrophil count > 1000/mm3
- •Platelet count > 60,000/mm3
- •Serum creatinine > 2.0 mg/dL
- •Total bilirubin > 4 mg/dL
- •AST (SGOT) and ALT (SGPT) > 5 x ULN.
- •Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix: H Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix: F Education and Counseling Guidance Document
- •Disease free of prior malignancies for > 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Use of any other experimental drug or therapy within 28 days of baseline.
- •Known hypersensitivity to thalidomide.
- •The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- •Any prior use of lenalidomide.
- •Concurrent use of other anti-cancer agents or treatments.
- •Known positive for HIV. (The effect of immune modulation of lenalidomide on patients who are HIV positive is unknown).
研究组 & 干预措施
Lenalidomide
Experimental
干预措施: lenalidomide (Drug)
结局指标
主要结局
Response Rate by Recist Criteria
时间窗: on average about every 2 months until progression, on average about 4 months.
radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed.
次要结局
未报告次要终点
研究者
howard safran
Principle Investigator
Brown University
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001Hepatocellular CarcinomaNCT00775073Gerhard Treiber33
终止
不适用
LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic TumorsHepatic CancerLiver NeoplasmsHepatocellular CancerLiver CancerNCT02649868National Institutes of Health Clinical Center (CC)19
已完成
2 期
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically RemovedLiver CancerNCT00006006National Cancer Institute (NCI)38
已完成
不适用
A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver CancersMetastatic Liver CancersHepatocellular CarcinomaNCT02828865National Taiwan University Hospital18
Unknown
3 期
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT00921531Fudan University200